Due to the preclinical success of PIM inhibitors, multiple small-molecule PIM inhibitors have been developed and entered clinical trials for the treatment of several cancer types, including B-cell lymphoma, acute myeloid leukemia, multiple myeloma, Hodgkin lymphoma, and prostate cancer [23]. The gene discussed is PIM1; the disease is prostate cancer.